Innogenia Therapeutics Not Exercised by MSD on IGT-302 Glaucoma Indication Option; No Obligation to Return 3.9 Billion Won in Research Funds
Innogenia Therapeutics has been notified by MSD that it will not exercise its research and development option for the IGT-302 glaucoma indication. However, the company has no obligation to return the 3 million USD (approximately 3.97555 billion won) in joint research and development funds it has alr

Innogenia Therapeutics has been notified by MSD that it will not exercise its research and development option for the IGT-302 glaucoma indication. However, the company has no obligation to return the 3 million USD (approximately 3.97555 billion won) in joint research and development funds it has already received.
According to a regulatory filing on the 9th, MSD decided not to exercise its R&D option for Innogenia Therapeutics' IGT-302 glaucoma indication. The company received the relevant official letter on November 7, Korea time.
What has been terminated this time is the opportunity to exercise the option under the glaucoma indication research agreement. Therefore, this cannot be interpreted as extending to the termination of all IGT-302 indications or the company's entire business.
There is also no issue regarding the return of research funds. Innogenia Therapeutics stated that it has no obligation to return the 3 million USD in joint R&D funds received from Eyebio under the relevant research agreement. These funds, totaling approximately 3.97555 billion won when converted to Korean won, were already received across 2023 and 2024.
The glaucoma indication option originated from a separate research agreement signed on October 31, 2022, before the company's KOSDAQ listing. Subsequently, when Eyebio was acquired by MSD in July 2024, the rights related to the option were also transferred to MSD.
Meanwhile, Innogenia Therapeutics reflected the date it received the non-exercise notification as both the date of confirmation of the fact and the decision date. Although the option exercise for the glaucoma indication has been terminated due to this notification, no obligation has arisen to return the joint R&D funds already received.
[This article received some assistance from AI in the writing process. The information provided is for reference purposes, and this publication bears no legal or financial responsibility for the use of such information.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



